Business · 02/08/2024
FDA Renewal of Psychopharmacologic Drugs Advisory Committee
The Food and Drug Administration (FDA) is renewing the Psychopharmacologic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on June 4, 2026, at the request of the Commissioner of Food and Drugs.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →